Investors have committed to subscribe for a further approximately 5.1 MSEK in Oncology Ventures ongoing rights issue

Hoersholm, Denmark, March 29, 2017 – As previously announced Oncology Venture Sweden AB (“Oncology Venture”) has already agreed on subscription commitments of approximately 18.9 MSEK, representing approximately 35.7 % of the issue volume in the ongoing rights issue. The company today announces that investors have committed to subscribe for a further approximately 5.1 MSEK in Oncology Ventures ongoing rights issue. Among that, Sass & Larsen ApS agreed to subscribe for an additional approximately 2.3 MSEK and Viggo Harboe 2006 Holding ApS about another 1 MSEK in addition to the subscription commitments which the parties earlier agreed on in the rights issue. The company's main shareholder Sass & Larsen ApS intends to utilize all of their subscription rights, corresponding to a total of approximately 7.4 MSEK. Viggo Harboe 2006 Holding ApS utilizes existing holdings of subscription rights and receive additional subscription rights. Thereby, Viggo Harboe 2006 Holding ApS is to subscribe for shares in the rights issue corresponding to a total amount of approximately 3.4 MSEK. In addition, Sune Hansen, Kian Grae Nielsen, Landsholdet Holding ApS, Claus Frisenberg and Christian Gabe agreed to subscribe for shares in the rights issue. These parties have received subscription rights from Medical Prognosis Institute A/S, Buhl Krone Holding ApS and DTU Innovation (Seed), which previously transferred subscription rights. Medial Prognosis Institute A/S has transferred subscription rights corresponding to 10.61% of the total number of shares in Oncology Venture, Buhl Krone Holding ApS has transferred subscription rights corresponding to 9.36% of the total number of shares in Oncology Venture and DTU Innovation (Seed) has transferred subscription rights corresponding to about 7.8% of the total number of shares in Oncology Venture.

“The fact that Oncology Ventures shareholders decide to invest further in the company is very important. We are very pleased that the interest in Oncology Venture is so big and that there is a strong belief in the company and its operations”, says Adjunct Professor Peter Buhl Jensen, M.D., CEO of Oncology Venture.

Prospectus (containing information on subscription commitments and the rights issue), teaser and subscription form is available via the company´s (www.oncologyventure.com) Sedermera Fondkommission´s (www.sedermera.se) and AktieTorget´s (www.aktietorget.se) respective websites.

For questions related to the rights issue, please contact:

Sedermera Fondkommission

Telephone: + 46 40-615 14 10

E-mail: info@sedermera.se

For further information, please contact:

This information is information that Oncology Venture Sweden AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, on March 29, 2017.

About Oncology Venture Sweden AB

Oncology Venture Sweden AB is engaged in the research and development of anti-cancer drugs via its wholly owned Danish subsidiary Oncology Venture ApS. Oncology Venture has a license to use Drug Response Prediction – DRP™ – in order to significantly increase the probability of success in clinical trials. DRP™ has proven its ability to provide a statistically significant prediction of clinical outcomes from drug treatment in cancer patients in 29 of the 37 clinical studies that were examined. The Company uses a model that alters the odds in comparison with traditional pharmaceutical development. Instead of treating all patients with a particular type of cancer, patients’ tumors genes are screened first and only those who are most likely to respond to the treatment will be treated. Via a more well-defined patient group, the risk and costs are reduced while the development process becomes more efficient. The current product portfolio: LiPlaCis for Breast Cancer, Irofulven developed from a fungus for prostate cancer and APO010 – an immuno-oncology product for Multiple Myeloma. Oncology Venture has spun out two companies in Special Purpose Vehicles: 2X Oncology Inc. a US based company focusing on Precision medicine for women’s cancers with a pipeline of three promising phase 2 product candidates and Danish OV-SPV 2 will test and potentially develop an oral phase 2 Tyrosine Kinase inhibitor.